Clinical Trials
High Risk Prostate Cancer

This Information is provided to help patients identify clinical trials for educational purposes and not to recruit patients for any specific trials. Patients should consult with their personal doctor and the trial sponsors for additional information on trials of interest.

Study to evaluate immunotherapy in combination with radiation in prostate cancer patients

Number: NCT01436968
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Advantagene, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Number: NCT01794793
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 4
Sponsor(s): Novartis Pharmaceuticals|Novartis
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Definitive Therapy to Treat Prostate Cancer

Number: NCT02716974
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sponsor Trial Information
Trial Location(s) and Contact(s)
Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer

Number: NCT02770391
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: 2
Sponsor(s): Case Comprehensive Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study to determine if anti-testosterone medications, when administered before, during, and after radiation, will be effective in preventing the prostate cancer from returning

Number: NCT02772588
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Memorial Sloan Kettering Cancer Center|Janssen Pharmaceuticals|Weill Medical College of Cornell University|University of Michigan
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Nanoparticles and Radiation or Radiation With Brachytherapy for Prostate Cancer

Number: NCT02805894
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Nanobiotix
Sponsor Trial Information
Trial Location(s) and Contact(s)
Apalutamide With or Without Abiraterone, Hormone, and Prednisone in Treating High-Risk Patients Undergoing Surgery

Number: NCT02949284
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Rutgers, The State University of New Jersey|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Number: NCT02960022
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Astellas Pharma Global Development, Inc.|Pfizer|Astellas Pharma Inc
Sponsor Trial Information
Trial Location(s) and Contact(s)
Trial of Androgen Deprivation Therapy and Radiation Versus Radiation Prostate Cancer

Number: NCT03056638
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Memorial Sloan Kettering Cancer Center|Ferring Pharmaceuticals|University of Texas Southwestern Medical Center|University of Michigan
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Screening Method for Detection of Metastasis Among High-risk Prostate Cancer Patients

Number: NCT03081884
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Emory University|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study to Evaluate Relugolix in Men With Advanced Prostate Cancer

Number: NCT03085095
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Myovant Sciences GmbH
Sponsor Trial Information
Trial Location(s) and Contact(s)
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Number: NCT03333616
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Dana-Farber Cancer Institute|Bristol-Myers Squibb
Sponsor Trial Information
Trial Location(s) and Contact(s)
Radiation Therapy With or Without Apalutamide in Treating Patients With Prostate Cancer

Number: NCT03371719
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): NRG Oncology|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer

Number: NCT03471650
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Progenics Pharmaceuticals, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Pembrolizumab Plus Androgen Receptor Targeting Prior to Prostatectomy for High Risk Patients

Number: NCT03753243
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: 2
Sponsor(s): Merck Sharp & Dohme Corp.|Astellas Pharma Inc|Portland VA Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Apalutamide in Patients With High‑Risk, Localized Prostate Cancer Who Are Candidates for Radical Prostatectomy (PROTEUS)

Number: NCT03767244
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: 3
Sponsor(s): Janssen
Sponsor Trial Information
Trial Location(s) and Contact(s)
Conventional ADT w/ or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT

Number: NCT03777982
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Dana-Farber Cancer Institute|Janssen Scientific Affairs, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer

Number: NCT03886493
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Regeneron Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s)

Total: 18 Clinical Trials

PHEN,Inc. © 2019 All rights reserved